The NUB designation for Zemcelpro® (dorocubicel) enables hospitals to immediately apply for temporary, supplementary reimbursement for its use. MONTREAL, Feb. 16The NUB designation for Zemcelpro® (dorocubicel) enables hospitals to immediately apply for temporary, supplementary reimbursement for its use. MONTREAL, Feb. 16

Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany

2026/02/16 20:30
5 min read
  • The NUB designation for Zemcelpro® (dorocubicel) enables hospitals to immediately apply for temporary, supplementary reimbursement for its use.

MONTREAL, Feb. 16, 2026 /PRNewswire/ – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, and its wholly owned subsidiary Cordex Biologics (Cordex), announced that Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy, has been granted Status 1 listing by the NUB (Neue Untersuchungs- und Behandlungsmethoden) program in Germany.

The NUB designation is a recognition that Zemcelpro® (dorocubicel) is supported by a relevant and growing body of clinical evidence and enables hospitals to immediately apply for temporary, supplementary reimbursement for its use while broader reimbursement pathways continue to be evaluated.  Notably, 220 hospitals across Germany have expressed interest in accessing Zemcelpro® (dorocubicel) through the NUB mechanism for the 2026 calendar year.

“NUB Status 1 represents a significant milestone for ExCellThera and Cordex and reflects both the innovative nature of Zemcelpro® (dorocubicel) and its benefit in in addressing a pressing unmet medical need in allogeneic haematopoietic stem cell transplantation,” said David Millette, CEO of ExCellThera. “Under its initial label, Zemcelpro® (dorocubicel) is indicated for patients with life threatening blood cancers who have limited therapeutic options.”

Zemcelpro® (dorocubicel) has recently received conditional marketing authorization from the European Commission for the treatment of adults with haematological malignancies requiring allogeneic haematopoietic stem cell transplantation following myeloablative conditioning, for whom no other suitable donor cells are available.

With NUB status 1 in place for Zemcelpro® (dorocubicel), Cordex will work closely with leading German stem cell transplant centers to support individual NUB applications and to further expand clinical adoption. In parallel, the company will invest in post-market registry participation, and in evidence and economic data generation to support longer-term reimbursement and inclusion of Zemcelpro® (dorocubicel) in clinical guidelines. Together, these elements strengthen Zemcelpro® (dorocubicel)’s commercial foundation in Germany and provide a constructive bridge toward future statutory reimbursement by the healthcare system.

The availability of Zemcelpro® (dorocubicel) in individual European countries depends on several factors, including completion of national reimbursement procedures. In the interim, Cordex will engage with national health authorities to enable early access for eligible patients and is engaging with leading stem cell transplantation centres to establish a future network of treatment sites for Zemcelpro® (dorocubicel) administration.

Additional regulatory filings are planned for Zemcelpro® (dorocubicel) with other health authorities, including in the US, Canada, the UK, and Switzerland.

Cordex is also actively seeking strategic partnerships to support and accelerate the commercialization of Zemcelpro® (dorocubicel) in Europe and other international markets.

About Zemcelpro®

Zemcelpro®, also known as UM171 Cell Therapy, is a novel personalized cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit.  

Zemcelpro® (dorocubicel), developed by Cordex, a wholly owned subsidiary of ExCellThera, has been evaluated in 120 patients with haematologic malignancies in clinical trials in the United States, Europe and Canada. Zemcelpro® (dorocubicel) has received orphan drug designation and regenerative medicine advanced therapy (RMAT) designations from the FDA as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification and priority medicines (PRIME) designation from the EMA.

Zemcelpro® (dorocubicel) has been tested in Phase 2 trials in patients with high and very high-risk acute leukemias and myelodysplasias who have limited treatment options with low survival outcomes and high incidence of relapse under the current standard of care, including patients with patients with TP53 mutations or other genetic abnormalities, patients requiring a second transplant, and patients with refractory or active disease. A pivotal Phase 3 trial in this patient population will be initiated as soon as possible.

The use of Zemcelpro® (dorocubicel) in other patient populations, including pediatric patients and patients with non-malignant haematological diseases, is also being investigated.

For complete product information, including Warnings and Precautions for Use and Adverse Reactions (and their appropriate management), please refer to the EU Summary of Product Characteristics (SmPC) for Zemcelpro®.

The product safety and efficacy have not yet been established by other regulatory agencies, such as the U.S. FDA, the MHRA and Health Canada.

About ExCellThera and UM171 Technology

ExCellThera is a world leader in enhanced blood stem cell therapies. ExCellThera’s proprietary EnhanceTM platform for cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the EnhanceTM platform, including the proprietary molecule UM171 which has a first-in-class mechanism of action for ex vivo expansion and metabolic fitness of HSCs. For additional information, visit excellthera.com, and follow us on LinkedIn.

Zemcelpro® is a registered trademark of ExCellThera or its related companies.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zemcelpro-dorocubicel-receives-nub-status-1-in-germany-302688424.html

SOURCE ExCellThera

Market Opportunity
nubcat Logo
nubcat Price(NUB)
$0.00285
$0.00285$0.00285
-0.69%
USD
nubcat (NUB) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Exploring Market Buzz: Unique Opportunities in Cryptocurrencies

Exploring Market Buzz: Unique Opportunities in Cryptocurrencies

In the ever-evolving world of cryptocurrencies, recent developments have sparked significant interest. A closer look at pricing forecasts for Cardano (ADA) and rumors surrounding a Solana (SOL) ETF, coupled with the emergence of a promising new entrant, Layer Brett, reveals a complex market dynamic. Cardano's Prospects: A Closer Look Cardano, a stalwart in the blockchain space, continues to hold its ground with its research-driven development strategy. The latest price predictions for ADA suggest potential gains, predicting a double or even quadruple increase in its valuation. Despite these optimistic forecasts, the allure of exponential gains drives traders toward more speculative ventures. The Buzz Around Solana ETF The potential introduction of a Solana ETF has the crypto community abuzz, potentially catapulting SOL prices to new heights. As investors await regulatory decisions, the impact of such an ETF on Solana's value could be substantial, potentially reaching up to $300. However, as with Cardano, the substantial market capitalization of Solana may temper its growth potential. Why Layer Brett is Gaining Traction Amidst established names, a new contender, Layer Brett, has started to capture the market's attention with its early presale stages. Offering a low entry price of just $0.0058 and promising over 700% in staking rewards, Layer Brett presents a tempting proposition for those looking to maximize returns. Comparative Analysis: ADA, SOL, and $LBRETT While both ADA and SOL offer stable investment choices with reliable growth, Layer Brett emerges as a high-risk, high-reward option that could potentially offer significantly higher returns due to its nascent market position and aggressive economic model. Initial presale pricing lets investors get in on the ground floor. Staking rewards currently exceed 690%, a persuasive incentive for early adopters. Backed by Ethereum's Layer 2 for enhanced transaction speed and reduced costs. A community-focused $1 million giveaway to further drive engagement and investor interest. Predicted by some analysts to offer up to 50x returns in coming years. Shifting Sands: Investor Movements As the crypto market landscape shifts, many investors, including those traditionally holding ADA and SOL, are beginning to diversify their portfolios by turning to high-potential opportunities like Layer Brett. The combination of strategic presale pricing and significant staking rewards is creating a momentum of its own. Act Fast: Time-Sensitive Opportunities As September progresses, opportunities to capitalize on these low entry points and high yield offerings from Layer Brett are likely to diminish. With increasing attention and funds being directed towards this new asset, the window to act is closing quickly. Invest in Layer Brett now to secure your position before the next price hike and staking rewards reduction. For more information, visit the Layer Brett website, join their Telegram group, or follow them on X by clicking the following links: Website Telegram X Disclaimer: This is a sponsored press release and is for informational purposes only. It does not reflect the views of Bitzo, nor is it intended to be used as legal, tax, investment, or financial advice.
Share
Coinstats2025/09/18 18:39
Tests 50-day EMA barrier near 183.00

Tests 50-day EMA barrier near 183.00

The post Tests 50-day EMA barrier near 183.00 appeared on BitcoinEthereumNews.com. EUR/JPY remains steady after three days of gains, trading around 182.70 during
Share
BitcoinEthereumNews2026/02/23 17:03
Moonshot MAGAX vs Shiba Inu: The AI-Powered Meme-to-Earn Revolution Challenging a Meme Coin Giant

Moonshot MAGAX vs Shiba Inu: The AI-Powered Meme-to-Earn Revolution Challenging a Meme Coin Giant

Discover how Moonshot MAGAX’s AI-powered meme-to-earn platform outpaces Shiba Inu with innovative tokenomics and growth potential in 2025.
Share
Blockchainreporter2025/09/18 03:15